SAR 31.95
(2.4%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 13.94 Million SAR | -45.75% |
2022 | 25.71 Million SAR | 158.88% |
2021 | 9.93 Million SAR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 3.61 Million SAR | 359.9% |
2023 Q2 | 13.16 Million SAR | -9.79% |
2023 Q4 | 786.66 Thousand SAR | -94.02% |
2023 FY | 13.94 Million SAR | -45.75% |
2022 Q2 | 9.5 Million SAR | 0.0% |
2022 FY | 25.71 Million SAR | 158.88% |
2022 Q4 | 14.59 Million SAR | 53.46% |
2021 FY | 9.93 Million SAR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 78.24 Million SAR | 82.175% |
Al-Dawaa Medical Services Company | 466.68 Million SAR | 97.011% |
Nahdi Medical Company | 960.95 Million SAR | 98.548% |
Al-Razi Medical Co. | 1.81 Million SAR | -669.597% |